Advertisement
Advertisement
U.S. Markets close in 5 hrs 45 mins
Advertisement
Advertisement
Advertisement
Advertisement

Alaunos Therapeutics, Inc. (TCRT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.5550-0.0050 (-0.32%)
As of 10:14AM EDT. Market open.
Advertisement

Alaunos Therapeutics, Inc.

8030 El Rio Street
Houston, TX 77054
United States
346 355 4099
https://www.alaunos.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees41

Key Executives

NameTitlePayExercisedYear Born
Mr. Kevin S. Boyle Sr.CEO & Director347.81kN/A1974
Mr. Michael WongVP of Fin. & Principal Accounting OfficerN/AN/A1980
Ms. Melinda LackeySr. VP of Legal & Sec.N/AN/A1977
Dr. David M. Mauney M.D.ConsultantN/AN/A1969
Dr. Drew C. Deniger Ph.D.VP of R&DN/AN/A1980
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is headquartered in Houston, Texas.

Corporate Governance

Alaunos Therapeutics, Inc.’s ISS Governance QualityScore as of July 31, 2022 is 7. The pillar scores are Audit: 10; Board: 8; Shareholder Rights: 3; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement